Randomized Trial: SGLT2 inhibitor Reduces Progression of Kidney Disease in Patients with Type 2 Diabetes and Nephropathy

16 Apr, 2019 | 02:52h | UTC

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy – New England Journal of Medicine (free for a limited period)

Commentary: Canagliflozin may offer renal protection in people with type 2 diabetes and CKD – Medicine Matters (free)

“among 1000 patients treated for 2.5 years, 21.2 individuals would need to be treated to prevent the composite primary outcome.” (from Medicine Matters)

 

Join our WhatsApp group

Free Updates in All Specialties!

A daily update on the latest medical news, practice-changing trials and guidelines

Stay Updated in Your Specialty
No spam, just news
Unsubscribe with one click

 

Daily

 

Weekly or Less Often 
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •